These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17212722)

  • 1. Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
    Jankowski MA; Patel H; Rouse JC; Marzilli LA; Weston SB; Sharpe PJ
    Haemophilia; 2007 Jan; 13(1):30-7. PubMed ID: 17212722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.
    D'Amici GM; Timperio AM; Gevi F; Grazzini G; Zolla L
    Electrophoresis; 2010 Aug; 31(16):2730-9. PubMed ID: 20737444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.
    Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M
    Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors.
    D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L
    Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
    Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of heterogeneity in commercially available recombinant factor VIII products.
    Baunsgaard D; Nielsen AD; Nielsen PF; Henriksen A; Kristensen AK; Bagger HW; Ezban M
    Haemophilia; 2018 Nov; 24(6):880-887. PubMed ID: 29726070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
    Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
    Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.
    Becker S; Simpson JC; Pepperkok R; Heinz S; Herder C; Grez M; Seifried E; Tonn T
    Thromb Haemost; 2004 Jul; 92(1):23-35. PubMed ID: 15213841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.
    Timperio AM; Gevi F; Grazzini G; Vaglio S; Zolla L
    Blood Transfus; 2010 Jun; 8 Suppl 3(Suppl 3):s98-104. PubMed ID: 20606759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII.
    Oh SH; Lee MY; Song DW
    Exp Mol Med; 1999 Jun; 31(2):95-100. PubMed ID: 10410309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a recombinant antihaemophilia-A factor (factor VIII-delta II) by matrix-assisted laser desorption/ionization mass spectrometry.
    Bihoreau N; Veillon JF; Ramon C; Scohyers JM; Schmitter JM
    Rapid Commun Mass Spectrom; 1995; 9(15):1584-8. PubMed ID: 8652881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.